Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota
International Journal of Molecular Sciences · 04.09.2025 · 26 (17) · 8616
DOI: 10.3390/ijms26178616 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.09.2025. Verfasst von Gül Çirkin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Gastroenterology Hepatology and Nutrition, Faculty of Medicine, Dokuz Eylul University, Izmir 35340, Türkiye. Hauptthemen laut MEDLINE: Vancomycin, Non-alcoholic Fatty Liver Disease, Gastrointestinal Microbiome, Cecum. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scientific Research Projects Coordination Unit of Dokuz Eylül University.
Abstract (Originalsprache)
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) encompasses a spectrum of liver conditions and involves gut–liver axis crosstalk. We aimed to evaluate whether oral vancomycin modifies liver injury and the cecal microbiota in a methionine–choline-deficient (MCD) diet model of NASH. Male C57BL/6J mice (n = 28) were block-randomized to four groups (n = 7 each) for 10 weeks: standard diet (STD); MCD diet; STD + vancomycin (VANC); and MCD + VANC (2 mg/mouse ≈ 50 mg/kg, every 72 h). After 10 weeks, liver tissues were analyzed for histological changes, cytokine levels [interleukin-6 (IL-6), interleukin-8 (IL-8), transforming growth factor beta 1 (TGF-β1)], and immunohistochemical markers [ubiquitin and cytokeratin 18 (CK18)]. Cecal microbiota composition was evaluated with 16S ribosomal RNA (rRNA) sequencing. The MCD reproduced key NASH features (macrovesicular steatosis, lobular inflammation). Vancomycin shifted steatosis toward a microvesicular pattern and reduced hepatocyte injury: CK18 and ubiquitin immunoreactivity were decreased in MCD + VANC vs. MCD, and hepatic IL-8 and TGF-β1 levels were lower in MCD + VANC vs. STD. Taxonomically, STD mice had Lactobacillus-rich microbiota. The MCD diet alone reduced alpha diversity (α-diversity), modestly lowered Firmicutes and increased Desulfobacterota/Fusobacteriota. Vancomycin alone caused a much larger collapse in richness, depleting Gram-positive commensals and promoting blooms of Escherichia–Shigella, Klebsiella, Parabacteroides, and Akkermansia. In the MCD + VANC group, vancomycin profoundly remodeled the microbiota, eliminating key commensals (e.g., Lactobacillus) and enriching Desulfobacterota, Fusobacteriota, and Campylobacterota. Oral vancomycin in the MCD model of NASH improved liver injury markers and altered steatosis morphology, but concurrently reprogrammed the gut into a low-diversity, pathobiont-enriched ecosystem with near-loss of Lactobacillus. These findings highlight a therapeutic trade-off—hepatic benefit accompanied by microbiome cost—that should guide microbiota-targeted strategies for NAFLD/NASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Gastroenterology Hepatology and Nutrition, Faculty of Medicine, Dokuz Eylul University, Izmir 35340, Türkiye.
- Department of Histology and Embryology, Faculty of Medicine, Dokuz Eylul University, Izmir 35340, Türkiye.
- Department of Physiology, Faculty of Medicine, Dokuz Eylul University, Izmir 35340, Türkiye.
- Experimental Animals Laboratory, Faculty of Medicine, Dokuz Eylul University, Izmir 35340, Türkiye.
- Department of Pediatrics, Faculty of Medicine, Eskisehir Osmangazi University, Eskisehir 26040, Türkiye.
ORCID-Profile: Gül Çirkin, Burcu Açıkgöz
Förderung
- Scientific Research Projects Coordination Unit of Dokuz Eylül University
Zitieren
APA
Çirkin, G., Aydemir, S., Açıkgöz, B., Çelik, A., Güler, Y., Kiray, M., Baykara, B., Dinleyici, E. Ç., & Öztürk, Y. (2025). Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota. International Journal of Molecular Sciences, 26(17), 8616. https://doi.org/10.3390/ijms26178616
Vancouver
Çirkin G, Aydemir S, Açıkgöz B, Çelik A, Güler Y, Kiray M, et al. Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota. International Journal of Molecular Sciences. 2025;26(17):8616. doi:10.3390/ijms26178616
BibTeX
@article{irkin2025,
author = {Çirkin, Gül and Aydemir, Selma and Açıkgöz, Burcu and Çelik, Aslı and Güler, Yunus and Kiray, Müge and Baykara, Başak and Dinleyici, Ener Çağrı and Öztürk, Yeşim},
title = {Hepatic Histopathological Benefit, Microbial Cost: Oral Vancomycin Mitigates Non-Alcoholic Fatty Liver Disease While Disrupting the Cecal Microbiota},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {17},
pages = {8616},
doi = {10.3390/ijms26178616}
}
EUVIMED